Across TCGA pan-cancer cohorts, UBE2Q2P5Y RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated UBE2Q2P5Y data layer.
The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher UBE2Q2P5Y RNA is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2Q2P5Y expression acts as an unfavorable survival marker.
OV are the cancer types where UBE2Q2P5Y RNA most reproducibly stratifies survival.